Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MPI | P34949 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11327119 | 0.82 | ADORA2A (0.62) | CYP19A1IDO1HSD17B1HSD17B2KDM4E | |
| SCHEMBL8549187 | 0.82 | HSD17B1 (0.68) | CYP19A1HSD17B1HSD17B2 | |
| SCHEMBL3769512 | 0.82 | KDM4E (0.42) | IDO1HSD17B1HSD17B2KDM4EALDH1A1 | |
| SCHEMBL20341648 | 0.82 | CYP19A1 (0.48) | CYP19A1IDO1HSD17B1HSD17B2KDM4E | |
| SCHEMBL14755837 | 0.82 | ALDH1A1 (0.51) | HSD17B1HSD17B2ALDH1A1NPC1RAB9A | |
| SCHEMBL8807502 | 0.82 | CYP19A1 (0.44) | CYP19A1IDO1HSD17B1HSD17B2KDM4E | |
| SCHEMBL930343 | 0.80 | ADORA3 (0.59) | NPC1RAB9ASMN1; SMN2TP53NFKB1 | |
| SCHEMBL9867185 | 0.78 | ALDH1A1 (0.45) | CYP19A1IDO1HSD17B1HSD17B2KDM4E | |
| SCHEMBL18003427 | 0.78 | CYP19A1 (0.41) | CYP19A1IDO1HSD17B1HSD17B2KDM4E | |
| SCHEMBL9028816 | 0.78 | CASP3 (0.52) | IDO1KDM4EALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-12-22 | — | — | US | disclosed |
| WO-2021046194-A1 | TRYPTOLINE-BASED BENZOTHIAZOLES AND THEIR USE AS ANTIBIOTICS AND ANTIBIOTIC RESISTANCE-MODIFYING AGENTS | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2021-03-11 | — | — | WO | disclosed |
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | CYP19A1 4132/4885IDO1 2283/4885HSD17B1 2009/4885 |
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | HNMT, TPH1, TPH2 | CYP19A1 2077/4885IDO1 41/4885HSD17B1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.